BioNTech (NASDAQ:BNTX) Stock: Insider Ugur Sahin Sells 30,000 Shares

Key Points

• CEO Ugur Sahin sold 30,000 BioNTech shares at an average price of $99.40, generating approximately $2.98 million. The transaction occurred under a pre-arranged Rule 10b5-1 trading plan and reduced his ownership by 7.31%.
• Sahin has conducted a series of stock sales in September, selling more than 300,000 shares across multiple transactions while retaining 380,209 shares valued at roughly $37.8 million.
• BioNTech shares traded near $99, while the company reported a quarterly loss and revenue decline. Despite mixed financial results, analysts maintained a consensus “Moderate Buy” rating with a $126 price target.

BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) CEO Ugur Sahin sold 30,000 shares of the stock in a transaction that occurred on Wednesday, September 23rd. The stock was sold at an average price of $99.40, for a total transaction of $2,982,000.00. Following the completion of the transaction, the chief executive officer owned 380,209 shares in the company, valued at $37,792,774.60. The trade was a 7.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Thursday, September 24th, Ugur Sahin sold 39,000 shares of BioNTech stock. The shares were sold at an average price of $98.99, for a total transaction of $3,860,610.00.
• On Tuesday, September 22nd, Ugur Sahin sold 46,000 shares of BioNTech stock. The stock was sold at an average price of $100.72, for a total value of $4,633,120.00.
• On Monday, September 21st, Ugur Sahin sold 33,000 shares of BioNTech stock. The shares were sold at an average price of $97.81, for a total value of $3,227,730.00.
• On Friday, September 18th, Ugur Sahin sold 30,000 shares of BioNTech stock. The stock was sold at an average price of $96.22, for a total value of $2,886,600.00.
• On Thursday, September 17th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $98.60, for a total value of $3,352,400.00.
• On Wednesday, September 16th, Ugur Sahin sold 15,000 shares of BioNTech stock. The shares were sold at an average price of $96.09, for a total value of $1,441,350.00.
• On Tuesday, September 15th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $96.49, for a total transaction of $3,280,660.00.
• On Monday, September 14th, Ugur Sahin sold 41,000 shares of BioNTech stock. The stock was sold at an average price of $99.45, for a total transaction of $4,077,450.00.
• On Friday, September 11th, Ugur Sahin sold 45,000 shares of BioNTech stock. The shares were sold at an average price of $96.93, for a total transaction of $4,361,850.00.
• On Thursday, September 10th, Ugur Sahin sold 20,500 shares of BioNTech stock. The shares were sold at an average price of $96.31, for a total value of $1,974,355.00.

BioNTech Price Performance

NASDAQ BNTX traded up $0.80 during trading hours on Thursday, reaching $99.26. The company's stock had a trading volume of 787,100 shares, compared to its average volume of 1,098,895. The firm's 50-day moving average price is $97.88 and its 200-day moving average price is $94.78. The company has a quick ratio of 7.80, a current ratio of 7.85 and a debt-to-equity ratio of 0.01. BioNTech SE Sponsored ADR has a 1 year low of $79.52 and a 1 year high of $124.00. The company has a market capitalization of $25.10 billion, a price-to-earnings ratio of -12.68 and a beta of 1.29.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing the consensus estimate of ($2.40) by ($0.13). BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.The company had revenue of $122.31 million during the quarter, compared to analysts' expectations of $180.18 million. During the same quarter in the previous year, the firm earned ($1.60) EPS. The firm's revenue for the quarter was down 59.5% compared to the same quarter last year. On average, equities research analysts predict that BioNTech SE Sponsored ADR will post -6.37 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

BNTX has been the topic of a number of research analyst reports. Morgan Stanley decreased their target price on BioNTech from $126.00 to $119.00 and set an "overweight" rating on the stock in a research report on Wednesday, July 8th. Jefferies Financial Group reaffirmed a "buy" rating on shares of BioNTech in a report on Monday, June 1st. Canaccord Genuity Group lowered their target price on BioNTech from $142.00 to $136.00 and set a "buy" rating for the company in a research report on Monday, August 31st. Citigroup cut their target price on shares of BioNTech from $130.00 to $125.00 and set a "buy" rating for the company in a report on Wednesday, August 5th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of BioNTech in a research report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $126.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in BNTX. Larson Financial Group LLC increased its stake in BioNTech by 86.4% during the fourth quarter. Larson Financial Group LLC now owns 274 shares of the company's stock worth $26,000 after acquiring an additional 127 shares during the last quarter. Integrated Wealth Concepts LLC bought a new stake in shares of BioNTech in the 2nd quarter valued at approximately $39,000. Caitong International Asset Management Co. Ltd lifted its stake in shares of BioNTech by 1,012.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 556 shares of the company's stock valued at $53,000 after purchasing an additional 506 shares during the last quarter. Vestcor Inc purchased a new position in shares of BioNTech in the 4th quarter worth approximately $153,000. Finally, Rockefeller Capital Management L.P. boosted its holdings in shares of BioNTech by 328.6% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,856 shares of the company's stock worth $177,000 after purchasing an additional 1,423 shares during the period. Hedge funds and other institutional investors own 15.52% of the company's stock.

BioNTech Company Profile

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.